other material
confidence high
sentiment positive
materiality 0.75
MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC
MAIA Biotechnology, Inc.
- Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
- Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.
- 2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.
- Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.